Myelodysplastic Syndrome
Conditions
Keywords
MDS
Brief summary
Study WCMC IST-CTI-MDS evaluates the safety and tolerability of tosedostat in adult patients with pathologically confirmed MDS (\< 20% blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO) classification after failure of hypomethylating agent-based therapy.
Detailed description
This is a single-center, open label, two-arm phase II study of clinical activity of tosedostat in adult patients with MDS who have failed prior hypomethylating agent-based therapy. Arm A is defined as Revised International Prognostic Scoring Systems (IPSS-R) very low, low, and intermediate disease. Arm B is defined as IPSS-R high or very high risk disease. The two arms are separate and will enroll simultaneously. The dose of tosedostat will be 120 mg once a day continuously for each 28 day treatment cycle. Patients will be assessed for disease response, on average, every two cycles as defined in the protocol. If patient has no response as defined by the protocol after two cycles, azacitidine 75 mg/m2 SC or IV for 5 days may be combined with tosedostat, at the investigator's discretion.The primary endpoint the study is to evaluate the safety and efficacy of tosedostat in two groups of patients with myelodysplastic syndrome who have relapsed after or are refractory or intolerant to azacitidine or decitabine. The primary endpoint for patients with IPSS-R very low, low and intermediate disease is transfusion independence and the primary endpoint for patients with high or very high risk disease is overall survival.
Interventions
DRUGTosedostat
120 mg PO once daily continuously for each 28 day treatment cycle
Sponsors
CTI BioPharma
Weill Medical College of Cornell University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Able to understand and to provide written informed consent 2. At least 18 years of age with pathologically confirmed MDS (\<20% blasts in bone marrow, peripheral blood, or both) within 6 weeks prior to screening by WHO classification 3. Must have received at least 4 cycles of decitabine-based or 6 cycles of azacitidine-based therapy and are either refractory to, relapsed after or intolerant to prior therapy with either agent. * Primary failure/refractory: Stable or worsening disease after a minimum of 4 cycles of decitabine-based or 6 cycles of azacitidine-based therapy * Secondary failure/relapse: Bone marrow blast count increase or loss of hematologic response after initial treatment response with hypomethylating agent-based therapy * Intolerance: Intolerance of hypomethylating agent-based therapy regardless of number of cycles completed and clinical response 4. Progression (according to 2006 IWG criteria) at any time after initiation of subcutaneous or intravenous azacitidine or decitabine treatment per labeling during the past 2 years, defined as follows: * For patients with \<5% BMBL, ≥ 50% increase in BMBL to \>5% BMBL * For patients with 5-10% BMBL, ≥ 50% increase in BMBL to \>10% BMBL * For patients with 10-20% BMBL, ≥ 50% increase in BMBL to \>20% BMBL * For patients with 20-30% BMBL, ≥ 50% increase in BMBL to \>30% BMBL * Any of the following: * ≥ 50% decrease from maximum remission/response levels in granulocytes or PLT * Decrease in Hgb concentration by ≥2 g/dL * Transfusion dependence, defined as administration of at least 4 RBC units in the past 8 weeks before Screening (patients must have Hgb values \< 9 g/dL prior to transfusion to be considered), in the absence of another explanation. 5. Has failed to respond to, relapsed following, not eligible, or opted not to participate in BM transplantation 6. Patients with very low, low or intermediate risk MDS by the IPSS-R must be transfusion-dependent, with a packed red blood cell requirement of ≥ 2 units/month 7. Off azacitidine or decitabine for at least 2 weeks, off all other treatments for MDS for at least 4 weeks. Filgrastim (G-CSF) and EPO are allowed before and during the study as clinically indicated 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 9. Subjects must have adequate hepatic and renal function including the following: * Total bilirubin ≤ 1.5 x upper limit of normal (in the absence of Gilbert's syndrome) * AST and ALT ≤ 2.5 x upper limit of normal * Serum creatinine ≤ 1.5 x upper limit of normal 10. Must have acceptable recovery from clinically significant non-hematologic toxicity after prior therapy. 11. Must have a life expectancy of at least 2 months 12. Screening left ventricular ejection fraction (LVEF) greater than 50% as documented by transthoracic echocardiogram (TTE) 13. Female subject of child-bearing potential and male subjects with female partners of reproductive potential must use acceptable contraceptive methods (hormonal or barrier method of birth control; abstinence) for the duration of time on study and continue to do so for a further 3 months after the end of tosedostat treatment. Should a female subject become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 14. Able to comply with all study procedures during the study including all visits and tests 15. Willing to adhere to the prohibitions and restrictions specified in this protocol 16. Patient must sign an informed consent form (ICF) indicating that s/he understands the purpose of and procedures required for the study and is willing to participate.
Exclusion criteria
1. Presence of AML (≥20% blasts in bone marrow, peripheral blood, or both) 2. Presence of serious illness, medical condition, or other medical history, involving the heart, kidney, liver, or other organ system, including abnormal laboratory parameters, which, in the opinion of the Investigator, would be likely to interfere with a subject's participation in the study or with the interpretation of the results. 3. Have known active central nervous system disease or active, uncontrolled, clinically significant infection(s) 4. Have other active malignancies (including other hematologic malignancies) or other malignancies within 12 months before enrollment, except non-melanoma skin cancer or cervical intraepithelial neoplasia 5. Are receiving any other investigational therapy or protocol-prohibited therapy 6. Have received previous treatment with tosedostat 7. Pregnant or breastfeeding females 8. Any prior or co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the subject's participation in the study 9. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures 10. Significant\* cardiovascular disease defined as: * Active heart disease including myocardial infarction within 6 months prior to study entry * Symptomatic coronary artery disease * Uncontrolled or clinically significant arrhythmia, angina, congestive heart failure * Presence of clinically significant valvular heart disease * Presence of clinically significant conduction defect on screening ECG * Uncontrolled hypertension (i.e., systolic BP \>160mmHg, diastolic \>90 mmHg in repeated measurements) despite adequate therapy * Clinically significant atrial fibrillation \* Grade 3/4 in the CTCAE v4.0 grading would generally be considered clinically significant, although this remains a judgment for the Investigator to make. 11. LVEF ≤ 50% 12. Baseline troponin I and b-type natriuretic peptide \> Grade I 13. Prior exposure cardiotoxic agent, such as anthracycline, within 3 months of enrollment 14. Concomitant use of drugs that prolong QT/QTc interval except antibiotics, antifungals, and other antimicrobials used as standard of care for the treatment and prevention of infection and/or other such drugs clinically indicated for patient care. When use of concomitant medications with QT-prolonging potential is necessary, ECG must be repeated 4 hours post-dose on Day 1, on Day 3, and on Day 7, and as clinically indicated, relative to start of agent with QT-prolonging potential. 15. Gastrointestinal disorders that may interfere with absorption of drug 16. Active serious infection or sepsis 17. Clinically significant interstitial lung disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Over All Survival | from start of treatment until death, assessed up to a period of 3-4 years. | Survival following treatment to the date of death, assessed up to a period of 3-4 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response | Approximately 3 years | Overall response according to IWG 2006 criteira |
| One Year and Two Year Survival | from start of treatment to 1 year and 2 years post treatment initiation | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Patients Tosedostat 120 mg PO once daily will be administered.
Tosedostat: 120 mg PO once daily continuously for each 28 day treatment cycle | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | All Patients |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 11 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants |
| Age, Continuous | 72 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 7 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Region of Enrollment United States | 12 participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 9 / 12 |
| other Total, other adverse events | 12 / 12 |
| serious Total, serious adverse events | 8 / 12 |
Outcome results
Primary
Over All Survival
Survival following treatment to the date of death, assessed up to a period of 3-4 years.
Time frame: from start of treatment until death, assessed up to a period of 3-4 years.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| All Patients | Over All Survival | 15.9 months |
Secondary
One Year and Two Year Survival
Time frame: from start of treatment to 1 year and 2 years post treatment initiation
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Patients | One Year and Two Year Survival | One year survival | 8 Participants |
| All Patients | One Year and Two Year Survival | two year survival | 4 Participants |
Secondary
Overall Response
Overall response according to IWG 2006 criteira
Time frame: Approximately 3 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Patients | Overall Response | Complete Remission | 1 Participants |
| All Patients | Overall Response | Stable Disease | 8 Participants |
| All Patients | Overall Response | Non-evaluable | 3 Participants |